Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
AI-first clinical enablement company and developer of remote physical examination technology featuring FDA-cleared medical devices
Develops novel therapeutics for immune mediated diseases
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Develops interventional therapies for pulmonary hypertension and heart failure
Develops highly targeted, small molecule medicines for cancer and rare diseases
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Develops next-generation bispecific ADCs for cancer treatment
Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases
Develops small molecule correctors for diseases of protein misfolding
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Develops therapeutics for pulmonary diseases, specifically COPD